Langerhans cell histiocytosis (LCH): guidelines for diagnosis, clinical work-up, and treatment for patients till the age of 18 years.
Haupt R, Minkov M, Astigarraga I, Schäfer E, Nanduri V, Jubran R, Egeler RM, Janka G, Micic D, Rodriguez-Galindo C, Van Gool S, Visser J, Weitzman S, Donadieu J, Euro Histio Network. · 2013
Read Langerhans cell histiocytosis (LCH): guidelines for diagnosis, clinical work-up, and treatment for patients till the age of 18 years. by Haupt R, Minkov M, Astigarraga I, Schäfer E, Nanduri V, Jubran R, Egeler RM, Janka G, Micic D, Rodriguez-Galindo C, Van Gool S, Visser J, Weitzman S, Donadieu J, Euro Histio Network. (2013) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc4557042.txt.
Introduction
Riccardo Haupt leads a twelve-author expert group setting care guidelines for a rare childhood disease, in Pediatric Blood & Cancer in 2013. Langerhans cell histiocytosis gathers abnormal dendritic cells in organs, most often bone, skin, and the pituitary gland, though nearly any site can be hit. Care varied widely between centers.
The guidelines, built under the Euro Histio Net project, cover children up to age 18. The panel reviewed evidence published through 2012, graded it by evidence-based rules, and used expert consensus where data ran thin. They set out how to diagnose the disease, what the first work-up should check, how treatment should proceed, and how long-term follow-up should run, aiming to steady care across countries.
Catalog record
| CREATOR | Haupt R, Minkov M, Astigarraga I, Schäfer E, Nanduri V, Jubran R, Egeler RM, Janka G, Micic D, Rodriguez-Galindo C, Van Gool S, Visser J, Weitzman S, Donadieu J, Euro Histio Network. |
|---|---|
| YEAR | 2013 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 44 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
Langerhans Cell Histiocytosis (LCH): Guidelines for Diagnosis, Clinical Work-Up, and Treatment for Patients Till the Age of 18 Years By Riccardo Haupt, Milen Minkov, Itziar Astigarraga, Eva Schäfer, Vasanta Nanduri, Rima Jubran, R Maarten Egeler, Gritta Janka, Dragan Micic, Carlos Rodriguez-Galindo, Stefaan Van Gool, Johannes Visser Published in: Pediatric Blood & Cancer DOI: 10.1002/pbc.24367 ABSTRACT These guidelines for the management of patients up to 18 years with Langerhans cell histiocytosis (LCH) have been set up by a group of experts involved in the Euro Histio Net project who participated in national or international studies and in peer reviewed publications. Existing guidelines were reviewed and changed where new evidence was available in the literature up to 2012. Data and publications have been ranked according to evidence based medicine and when there was a lack of published data, consensus between experts was sought. Guidelines for diagnosis, initial clinical work-up, and treatment and long-term follow-up of LCH patients are presented. INTRODUCTION Langerhans cell histiocytosis (LCH) is a heterogeneous disease, characterized by accumulation of dendritic cells with features similar to epidermal Langerhans cells in various organs. Any organ or system of the human body can be affected, but those more frequently involved are the skeleton (80% of cases), the skin (33%), and the pituitary (25%). Other organs involved are the liver, spleen, the hematopoietic system and the lungs (15% each), lymph nodes (5–10%), and the central nervous system excluding the pituitary (2–4%). The clinical course may vary from a self-limiting disease to a rapidly progressive one that might lead to death. Between 30% and 40% of patients may develop permanent adverse sequelae. Treatment options vary depending on the extent of the disease and the severity at onset. Response to front-line treatment is an important information to adapt the therapeutic strategy. As LCH is a rare disease, only a limited number of large surveys or of randomized clinical trials are available in the literature and many aspects of the management of patients remain obscure or controversial. The presented guidelines are based on published evidence and the clinical expertise of the authors. They are intended to provide guidance with respect to diagnosis and clinical work-up of LCH occurring in patients <18 years old. The recommendations can neither replace the physician's own professional judgement nor consider all special clinical circumstances which may apply to individual cases. METHODS This document is derived from the project Euro Histio Net 2008, a reference network (http://www.eurohistio.net) for LCH and associated syndromes in the European Union which received funding within the framework of the Public Health Program. The guidelines were designed and established by European and North American physicians considered to be experts in the field of pediatric histiocytic disorders. They are active members of the international medical society of histiocytoses “Histiocyte Society” (HS), of the European national societies of Hematology/Oncology, and of their respective national groups for the study and treatment of these diseases. The guidelines have been developed for use as recommended practice in the evaluation and treatment of children and teenagers up to 18 years with LCH. Scientific articles published in peer-reviewed journals up to January 2012 were systematically reviewed. In addition to the medical literature, the following guidelines are a synthesis of different international and national guidelines and recommendation documents. Evidence was ranked in four levels [1, 2]: (A) meta-analyses, high quality systematic reviews, or randomized controlled trials with a low risk of bias; (B) systematic reviews of case–control or cohort studies; (C) non-analytic studies; for example, case reports, case series, small retrospective studies; (D) expert opinion. Level of agreement between experts and data was ranked in three classes: (2) general agreement between all experts or between available studies; (1) discussed recommendation, but no formal objections between experts or mild difference between studies, without contradiction for the main endpoint; (0) divergence of opinion or contradictory results for the main endpoint. Langerhans Cell Histiocytosis Diagnosis Since LCH may affect any organ or system of the body, the condition should be considered whenever suggestive clinical manifestations occur in the skin, bone, lung, liver, or CNS. Table I shows a list of differential diagnoses to be considered depending on presenting complaints, signs, or symptoms. The diagnosis is clinicopathologic and should only be made in the appropriate clinical setting to prevent a misdiagnosis in the presence of normal reactive Langerhans cells, particularly in regional lymph nodes. In addition to clinical and radiological features, LCH diagnosis should always be based on histological and immunophenotypic examination of lesional tissue (agreement: 2), that should be taken from the most easily accessible, yet representative lesion. [Table: Differential Diagnosis for Manifestations of Langerhans Cell Histiocytosis] There is a well defined histologically characteristic appearance of the LCH lesions on hematoxylin and eosin stained sections, but positive CD1a and/or CD207 (Langerin) staining of the lesional cells is required for a definitive diagnosis [3–6] (agreement: 2). Electron microscopy is no longer needed (agreement: 2), since it has been shown that the expression of Langerin correlates with the ultrastructural presence of Birbeck granules. Diagnostic confirmation may be a challenge in some circumstances (e.g., liver specimens), where Birbeck granules are not present and CD1a and/or Langerin may be negative because LCH cells have regressed after having caused sclerosing cholangitis and Cirrhosis [7]. In rare cases the risk of biopsy may outweigh the need for a definitive diagnosis, and therefore the risk/benefit ratio should be carefully assessed. This is the case in patients with isolated involvement of a vertebral body without an adjacent soft tissue component, as in case of vertebra plana, or with isolated involvement of the odontoid peg. If the decision to avoid or postpone a biopsy is made, every effort should be made to rule out other conditions that might lead to a similar radiological finding (Table I). Patients without a histologically confirmed diagnosis need to be carefully monitored by appropriate imaging for at least the next 6 months in order to reassess the need for biopsy and its justification, in order to exclude a malignancy. Pretreatment Clinical Evaluation Once the diagnosis of LCH has been ascertained it is important to collect further baseline information in order to decide on a therapeutic approach. A complete history should include special reference to the nature and duration of symptoms. Specific symptoms to be sought are: pain, swelling, skin rashes, otorrhea, fever, loss of appetite, diarrhea, poor weight gain, growth failure, polydipsia, polyuria, respiratory symptoms, irritability, behavioral, and neurological changes. A detailed examination should be performed at the onset and at each follow-up visit. Currently there is no specific biological marker of disease activity, however, there is a general agreement (agreement: 2) that biochemical and imaging evaluation at diagnosis and at disease reactivation should include the mandatory investigations listed in Table II. Certain scenarios might require additional testing; the recommended laboratory investigations, imaging, or specialized clinical assessments upon specific indication are shown in Table III; the detailed protocol for head MRI is provided in (Supplemental Appendix I). [Table: Laboratory and Radiographic Evaluation of Children With LCH] [Table: Specific Clinical Scenarios and Recommended Additional Testing in Children With LCH] Defining Organ Involvement, Risk Organs, and CNS (Central Nervous System) Risk Lesions The findings of the pretreatment clinical evaluation allow definition of organ involvement based